Techno Drugs Ltd. (DSE:TECHNODRUG)

Techno Drugs Statistics

Total Valuation

Techno Drugs has a market cap or net worth of BDT 3.89 billion. The enterprise value is 6.16 billion.

Market Cap	3.89B
Enterprise Value	6.16B

Important Dates

The next estimated earnings date is Thursday, January 29, 2026.

Earnings Date	Jan 29, 2026
Ex-Dividend Date	Nov 20, 2025

Share Statistics

Techno Drugs has 132.00 million shares outstanding. The number of shares has increased by 30.38% in one year.

Current Share Class	132.00M
Shares Outstanding	132.00M
Shares Change (YoY)	+30.38%
Shares Change (QoQ)	+0.00%
Owned by Insiders (%)	66.80%
Owned by Institutions (%)	n/a
Float	37.83M

Valuation Ratios

The trailing PE ratio is 18.32.

PE Ratio	18.32
Forward PE	n/a
PS Ratio	1.20
PB Ratio	0.95
P/TBV Ratio	0.95
P/FCF Ratio	n/a
P/OCF Ratio	21.66
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.61, with an EV/FCF ratio of -10.82.

EV / Earnings	28.56
EV / Sales	1.90
EV / EBITDA	8.61
EV / EBIT	8.95
EV / FCF	-10.82

Financial Position

The company has a current ratio of 2.48, with a Debt / Equity ratio of 0.65.

Current Ratio	2.48
Quick Ratio	1.15
Debt / Equity	0.65
Debt / EBITDA	3.72
Debt / FCF	-4.68
Interest Coverage	1.64

Financial Efficiency

Return on equity (ROE) is 5.36% and return on invested capital (ROIC) is 6.51%.

Return on Equity (ROE)	5.36%
Return on Assets (ROA)	5.94%
Return on Invested Capital (ROIC)	6.51%
Return on Capital Employed (ROCE)	11.44%
Revenue Per Employee	2.25M
Profits Per Employee	149,956
Employee Count	1,438
Asset Turnover	0.45
Inventory Turnover	1.86

Taxes

In the past 12 months, Techno Drugs has paid 53.57 million in taxes.

Income Tax	53.57M
Effective Tax Rate	19.90%

Stock Price Statistics

The stock price has decreased by -18.06% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-18.06%
50-Day Moving Average	30.33
200-Day Moving Average	31.52
Relative Strength Index (RSI)	44.46
Average Volume (20 Days)	468,187

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Techno Drugs had revenue of BDT 3.23 billion and earned 215.64 million in profits. Earnings per share was 1.61.

Revenue	3.23B
Gross Profit	1.40B
Operating Income	688.44M
Pretax Income	269.21M
Net Income	215.64M
EBITDA	n/a
EBIT	688.44M
Earnings Per Share (EPS)	1.61

Balance Sheet

The company has 399.11 million in cash and 2.66 billion in debt, giving a net cash position of -2.27 billion or -17.16 per share.

Cash & Cash Equivalents	399.11M
Total Debt	2.66B
Net Cash	-2.27B
Net Cash Per Share	-17.16
Equity (Book Value)	4.10B
Book Value Per Share	31.04
Working Capital	2.06B

Cash Flow

In the last 12 months, operating cash flow was 179.81 million and capital expenditures -749.22 million, giving a free cash flow of -569.41 million.

Operating Cash Flow	179.81M
Capital Expenditures	-749.22M
Free Cash Flow	-569.41M
FCF Per Share	-4.31

Margins

Gross margin is 43.18%, with operating and profit margins of 21.29% and 6.67%.

Gross Margin	43.18%
Operating Margin	21.29%
Pretax Margin	8.33%
Profit Margin	6.67%
EBITDA Margin	n/a
EBIT Margin	21.29%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 1.00, which amounts to a dividend yield of 3.39%.

Dividend Per Share	1.00
Dividend Yield	3.39%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	21.91%
Buyback Yield	-30.38%
Shareholder Yield	-26.95%
Earnings Yield	5.54%
FCF Yield	-14.62%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Techno Drugs has an Altman Z-Score of 2.17 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.17
Piotroski F-Score	5